Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732248 | 0.76 | EGLN2 (0.37) | EGLN2 | |
| SCHEMBL250157 | 0.59 | DYRK1A (0.44) | — | |
| SCHEMBL1044933 | 0.57 | CHEK1 (0.34) | EGLN2 | |
| SCHEMBL9832005 | 0.57 | EGLN2 (0.38) | EGLN2EGLN1 | |
| SCHEMBL1368505 | 0.57 | EGLN2 (0.46) | EGLN2 | |
| SCHEMBL31329857 | 0.57 | EGLN2 (0.42) | EGLN2EGLN1 | |
| SCHEMBL18076845 | 0.57 | EGLN2 (0.47) | EGLN2 | |
| SCHEMBL3547481 | 0.55 | EGLN2 (0.45) | EGLN2 | |
| SCHEMBL7711671 | 0.55 | EGLN2 (0.53) | EGLN2 | |
| SCHEMBL14937452 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236112-B2 | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20210079021-A1 | CRYSTAL FORM AND SALT FORM OF TGF-BRI INHIBITOR AND PREPARATION METHOD THEREFOR | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-18 | — | — | US | disclosed |
| CN-109415341-B | Benzotriazole-derived alpha, beta unsaturated amide compounds as TGF-beta R1 inhibitor | 劲方医药科技(上海)有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3470409-B1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3470409-A1 | BENZOTRIAZOLE-DERIVED AND UNSATURATED AMIDE COMPOUND USED AS TGF- R1 INHIBITOR | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017215506-A1 | BENZOTRIAZOLE-DERIVED Α AND Β UNSATURATED AMIDE COMPOUND USED AS TGF-ΒR1 INHIBITOR | 南京明德新药研发股份有限公司 | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | TGFBR1, TGFBR2, TGFB1 | EGLN2 1286/4885EGLN1 1213/4885 |
| US-11236112-B2 | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor | TGFBR1, TGFBR2, TGFB1 | EGLN2 4663/4885EGLN1 4526/4885 |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | TGFBR1, TGFBR2, TGFB1 | EGLN2 1352/4885EGLN1 1222/4885 |
| US-20210079021-A1 | CRYSTAL FORM AND SALT FORM OF TGF-BRI INHIBITOR AND PREPARATION METHOD THEREFOR | TGFBR1, TGFBR2, TAB1 | EGLN2 4723/4885EGLN1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.